<div id="readability-page-1">02:39 PM EDT, 05/14/2026 (MT Newswires) -- (Updates with latest stock price movement in the headline and first paragraph, Q1 earnings in the second through sixth paragraphs.)Regenxbio's ( RGNX ) shares were down about 36% in Thursday afternoon trading after its Q1 swung to a loss and revenue declined.The company reported a Q1 net loss Thursday of $1.72 per diluted share, swinging from earnings of $0.12 a year earlier.Analysts polled by FactSet expected a loss of $1.34.Revenue for the quarter ended March 31 fell to $6.4 million from $89.0 million a year earlier.Analysts surveyed by FactSet expected $25.8 million.The company expects its cash, cash equivalents and marketable securities of $150.5 million as of March 31 to fund its operations into early 2027.Separately, the company said Thursday its investigational gene therapy RGX-202 met the primary endpoint in the pivotal phase III portion of the Affinity Duchenne trial for Duchenne Muscular Dystrophy.The company said 93% of patients achieved over 10% microdystrophin expression at week 12.Regenxbio ( RGNX ) said it is preparing to pursue accelerated approval based on the data and is targeting a potential commercial launch in 2027.Price: 6.47, Change: -3.57, Percent Change: -35.56 MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

RGNX

納斯達克生物科技指數 ETF - iShares Nasdaq

2 倍做多納斯達克生物技術 ETF - ProShares

紐交所高增長板生物技術指數 ETF - First Trust

動態生物技術與基因組 ETF - Invesco

標普生物技術 3 倍做多 - Direxion

醫藥突破 ETF - ALPS

生物科技 ETF - VanEck Vectors

IBBQ

標普生物技術 ETF - SPDR

Regenxbio 的股價在報告第一季度每股攤薄淨虧損 1.72 美元后下跌了 36%，而去年同期的收益為每股 0.12 美元。收入從 8900 萬美元降至 640 萬美元，未能達到分析師的預期。該公司擁有 1.505 億美元的現金，可以支持其運營到 2027 年初。然而，其基因療法 RGX-202 在第三階段試驗中達到了主要終點，計劃申請加速批准，並有望在 2027 年進行商業發佈

Update: Regenxbio Shares Fall After Q1 Swings to Loss, Revenue Declines; Phase 3 Study of RGX-202 Meets Primary Endpoint

fidelity

Regenxbio

Invesco Nasdaq Biotechnology ETF

輝盛研究系統

更新：Regenxbio 股價在第一季度由盈轉虧後下跌，收入減少；RGX-202 的第三階段研究達到了主要終點